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BUFFER SYSTEMS AND BIOCOMPATIBILITY IN PERITONEAL DIALYSIS
Introduction
The field of peritoneal dialysis (PD) is undergoing a re-
juvenation process exemplified by advances at multiple
levels: patient outcomes, practice enhancement, delivery
systems, dialysis solutions, and basic research. The vin-
dication of peritoneal dialysis as a robust method of re-
nal replacement therapy with wide suitability to various
patient groups has been amply documented. Patient out-
comes show progressive improvements across the globe.
The practice of PD has benefited from the formulation
of clinical guidelines that help establish care pathways
for quality delivery of therapy. While debate still con-
tinues on small-solute clearance targets, the overall sys-
tematization of care standards is a welcome outcome.
Improvements in connectology and greater sophistica-
tion in automated delivery systems are significantly help-
ing to reduce complications and enhance the quality of
life of patients on PD. Novel dialysis solutions that ad-
dress previously unmet clinical needs are becoming part
of standard practice in Europe, North America, and Asia
and making encouraging beginnings in other parts of
the world. Finally, basic research in PD is reflecting the
dynamism of the age of genomics and proteomics.
The present supplement to Kidney International at-
tempts to encapsulate information related to the flour-
ishing of renal science in the field of peritoneal dialysis,
with an emphasis on new insights into the role of new dial-
ysis solutions and their importance to buffer systems and
membrane biocompatibility. Guo and Mujais open the
series with a review of current outcomes of patients on
PD in North America, illustrating the remarkable success
story of the therapy and its continuing favorable evolu-
tion. They document the success of PD both when it is
the first renal replacement modality as well as when it
is used in patients who have had a vintage therapy with
other modalities, such as hemodialysis and transplanta-
tion. The enhanced survival of patients on PD is a strong
stimulus to considerations of optimization of dialytic care
to meet the requirements of long-term success with the
therapy.
Mehrotra et al present a detailed and scholarly review
of the impact of correction of acid-base balance on the
biologic underpinnings of good health. They examine the
consequences of failure of correction of uremic metabolic
acidosis and the expected benefits of interventions at
metabolic and end-organ levels. The state of correction of
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acid-base balance with standard PD solutions is described
by Mujais in a report of the largest series of patients on
manual, as well as automated, PD in North America. The
success of PD in correcting acidosis in the majority of
patients can be contrasted with the lesser success of in-
termittent therapies. The determinants of acid-base bal-
ance are examined in detail with interesting distinctions
observed between manual and automated forms of PD.
The topic is further developed in the review by Heim-
burger and Mujais, which details the pathways followed
by buffer moieties. They describe the distinct behavior
of buffer transport under the distinct conditions of single
buffer systems with the limitations of these systems as far
as regulatory control and non-physiologic conditions, and
illustrate the operational advantages of complementary
buffer systems.
The relevance of the introduction of novel solutions for
PD is put into perspective by the paper of Williams et al.
They describe the insights gleaned from a biopsy registry
rich in material from patients on standard lactate-based
solutions. Albeit cross-sectional, the large representation
of differing patient vintage on the therapy, as well as the
well-chosen control populations, allows the authors to
delineate a natural history of the peritoneal membrane
with traditional solutions. The factors that may have reg-
ulated this natural history, as well as the framework for
elaboration of future advances in the field of preservation
of the peritoneal membrane, are presented by Holmes
and Faict. Their paper offers a clear and systematic back-
ground for the papers that follow.
Hoff takes this issue to the next level. After offering a
scholarly and detailed examination of the elements of bio-
compatibility of dialysis solutions in general, she delves
into an exhaustive review of the in vitro studies that have
been performed to evaluate the biocompatibility of a dial-
ysis solution formulated at physiologic levels for pH, bi-
carbonate, and pCO2, and the use of a complementary
buffer system of bicarbonate/lactate that allows delivery
of an adequate buffer mass for replenishment of physio-
logic stores without exceeding the physiologic concentra-
tions of the prevalent bicarbonate/pCO2 buffer system.
The paper by ter Wee et al then offers a survey of
the explorations of biocompatibility in experimental an-
imal models of PD, expounding on the advantages and
limitations of such work and offering exciting glimpses
of the promises of new solutions. The clinical counter-
part of this work is found in the paper by Mackenzie
et al. These authors offer the results of the creative
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approach that allows the application of sophisticated an-
alytical probing of relevant clinical material and illustrate
the value of studying peritoneal cells ex vivo, and solu-
ble cell markers, as windows into the health and behavior
of resident and transient cells in the peritoneal space.
The results of this approach, which illustrate the bene-
fits of physiologic solutions with complementary buffer
systems, are also presented. An original contribution by
Skoufos et al showcases the biocompatibility of a variant
of a complementary bicarbonate/lactate buffer solution
with a lower total buffer mass. The value that two comple-
mentary physiologic solutions with differing total buffer
mass, but with physiologic levels of the major extracellu-
lar buffer system (bicarbonate/pCO2, pH), lies in is the
ability to titrate buffer delivery to the particular needs of
individual patients.
The following two papers describe the clinical experi-
ence with the complementary bicarbonate/lactate buffer
system solution in patients on continuous ambulatory
peritoneal dialysis (CAPD) and ambulatory peritoneal
dialysis (APD). Pecoits-Filho et al review the results
of studies in CAPD and show the benefits of the solu-
tion as it pertains to correction of metabolic acidosis,
elimination of pain on infusion, and overall positive im-
pact on peritoneal membrane health. Dratwa et al present
the original findings of the use of the complementary
buffer solution in patients on APD. They reproduce
in this population the same benefits as in patients on
CAPD and further demonstrate the value of two buffer
concentrates in meeting the clinical needs of different
patients.
The optimization of buffer composition is not the only
advance in peritoneal dialysis solutions composition. The
use of alternate osmotic agents helps expand the im-
pact of dialysis solutions on patient health. The use of
amino acids as osmotic agents offers the advantage of
replacing peritoneal losses of proteins and amino acids,
contributing to the nutritional intake of patients with a
non-carbohydrate source of calories, and offering a so-
lution with excellent biocompatibility. The replacement
of glucose with icodextrin offers a dramatic clinical en-
hancement of ultrafiltration for the long dwell, and re-
duces the glucose exposure of the peritoneum. The use
of this solution has been associated with major salutary
developments, such as regression of left ventricular hy-
pertrophy, better fluid volume control, reduction in blood
sugar deviations, and attenuation of hyperlipidemia. An
approach that combines the benefits of solutions with al-
ternate osmotic agents and solutions with optimal buffer
composition is intuitively obvious. Vardhan et al develop
this theme by first reviewing the advantages of the indi-
vidual solutions and then by illustrating the synergism of
their combined use in offering discrete and quantifiable
clinical benefits and a low-glucose dialytic regimen.
In the final contribution to this supplement, Pecoits-
Filho et al present a visionary description of the full
potential value of enhancing the composition of dialy-
sis solutions. They develop the concept that the impact
of solution biocompatibility goes beyond the peritoneal
membrane and affects systemic functions significantly.
Drawing on recent explorations in the areas of systemic
inflammation, oxidative stress, and ingestive behavior,
among others, they offer the unifying concept of global
biocompatibility that encompasses the regional and sys-
temic effects of dialysis solutions.
The contributions in this supplement make it clear that
the present status of peritoneal dialysis contains the seeds
of a bright future, as well as indications of the path to fol-
low in future innovation. To be able to care for increas-
ing numbers of patients with peritoneal dialysis requires
that a policy of iterative innovation be pursued consis-
tently and with vigor at all levels, and we hope that this
supplement illustrates the results of such an approach.
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NOTE ON THE COVER ART
John William Waterhouse (1849–1917) was an English
painter whose art belongs to the school of Victorian
Romanticism. Close to the Pre-Raphaelites in his themes,
he focused on subjects from the Corpus of Western writ-
ings, drawing his inspiration from Homer, Shakespeare,
European legends, and the history of Christian martyrs.
His works carry such titles as Hylas and the Nymphs,
Ophelia, St Cecilia, St Eulalia, La belle dame sans merci,
The Lady of Shalot, Ulysses and the Sirens, and a few
of Circe, among others. The painting reproduced on the
cover of this supplement is titled The Danaı¨des, a work
painted in 1903 and currently in a private collection.
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